In this preclinical evaluation we have compared the efficacy of three clinical CD34
Haematopoietic stem and progenitor cells in bone marrow and blood are contained in a compartment of cells expressing the surface membrane antigen CD34. 1 This antigen is a complex stage-specific molecule with highest expression on early progenitors (CD34 bright ), and the density decreases progressively as cells mature. [1] [2] [3] The CD34 bright population includes cells with features of long-term lymphopoiesis and myelopoiesis in vitro, as well as mediating T, B, myelomonocytic and megakaryocytic repopulation in vivo. 1, [4] [5] [6] [7] The CD34 dim population contains lineage-committed progenitors without ability to provide long-term haematopoiesis. 6, 7 There are indications that such clonogenic progenitors may be responsible for the initial fast recovery following peripheral blood progenitor transplantation, however, this has not been proven. 8, 9 A number of approaches have been developed to enrich cells expressing the CD34 antigens which have been proved to engraft baboons and humans. [10] [11] [12] Preclinical studies have suggested several clinical applications of highly purified CD34 ϩ cells, including tumour cell purging. Enrichment of CD34 ϩ cells has been proven to deplete tumour cells from autografts, [13] [14] [15] [16] [17] [18] and is necessary for ex vivo expansion of progenitor cells. Furthermore, highly purified CD34 ϩ cells are essential for optimal cytokine-mediated expansion and differentiation in short-term culture. 19, 20 All devices in clinical practice are based on anti-CD34 antibodies which bind to the class I or II epitopes of the stagespecific molecule 2 to avoid competition with the class III epitopes used for flow cytometry evaluation of purity and yield of CD34 ϩ cells. Despite the development of several clinical instruments for graft processing by CD34 ϩ enrichment, no standardisation has been established to evaluate the procedure, including the registration of purity, yield and recovery as well as the delineation of the risk of selective loss of specific progenitor subsets. No device is ideal and evaluation of the procedures should be based on the known limitations of the enrichment procedure. First nonspecific adherence of random cells released with the target cells will affect purity and contamination with unwanted cells, like tumour cells. Second, incubation and washing procedures as well as adherence will ultimately affect the yield and total recovery of target cells. Third, the selected class I and II anti-CD34 antibody entail the risks of selective loss due to the stagedependent antigen and epitope density.
Standardisation of stem cell processing is urgently needed as the graft quality and safety may interfere with the clinical outcome. Recent published data 21, 22 as well as data from the Nordic Stem Cell Laboratory Group (NSCL-G) have documented a delayed platelet recovery following transplantation of processed autografts. The background is unknown and needs to be identified to allow us to generate safety and quality recommendations for ex vivo enrichment of autografts. Within the Nordic area, several clinical pilot studies have been activated in patients with multiple myeloma and non-Hodgkin's lymphoma including purging strategies based in part on CD34 ϩ cell enrichment. Therefore, we have compared different clinical devices by evaluating safety performance, purity, yield, and risk for selective loss of progenitors. This evaluation has documented a procedure related loss of 'late' lineage-specific progenitors, most likely due to decreased density or lack of class I and II epitopes on the lost cells, and a selective loss of 'early' uncommitted CD34 bright cells during column separation. It is unknown if such observations may in part explain the observed delayed platelet recovery. This has to be studied in future clinical trials based on standard procedures.
Materials and methods
This is a one centre preclinical comparison of three different methods for CD34 ϩ cell enrichment performed in three different annual periods from 1994 to 1998. All patients were considered candidates for high-dose therapy supported by autologous stem cell transplantation.
Mobilisation and stem cell collection
Different priming procedures were used in patients with haematological malignancies, either rhG-CSF alone in a dose of 10 g/kg/day subcutaneously or high-dose (4 g/m 2 ) cyclophosphamide (HDCy) supported by MESNA and hyperhydration as described by To et al. 8 At the end of the nadir period, rhG-CSF was added in a dose of 10 g/kg/ day given as subcutaneous injections. In breast cancer patients, stem cells were mobilised with CEF (cyclophosphamide 1200 mg/m 2 , epirubicin 60 mg/m 2 , 5-fluorouracil 600 mg/m 2 ) administered on day 1, followed by rhG-CSF 10 g/kg/day from day 2 until leukapheresis was completed.
In all priming procedures, blood levels of CD34 ϩ cells were monitored daily during priming and mobilisation, and leukapheresis was performed when blood levels of CD34 ϩ cells exceeded 20 ϫ 10 3 /ml blood. 23, 24 Leukapheresis continued until a total yield of at least 2 ϫ 10 6 CD34 ϩ cells/kg was obtained. Leukapheresis was performed on a Fenwal CS 3000 Plus blood cell separator (Fenwal Laboratories, Deerfield, IL, USA). A total blood volume of 10 l per apheresis was processed at a flow rate of 50-70 ml/min.
Stem cell processing
Leukapheresis products were processed immediately and in accordance with the manufacturer's instructions.
Amgen cell selection device (ACSD) (AmCell Corporation, Sunnyvale, CA, USA): Each product was transferred to a 600 ml transfer bag with coupler and adjusted to a volume of 95 ml and 7.5 ml of anti-CD34 antibody conjugated to iron-dextran microbeads was added. The antibody incubation was performed at ambient temperature with continuous mixing for 30 min. After the incubation period, the cells were washed twice with 500 ml of PBS buffer with 0.5% (w/v) HSA and 1 mm EDTA and resuspended to 100 ml with PBS buffer. The bag with labelled cells was attached to the microaggregate blood transfusion filter and hung on the ACSD. PBS was used to flush air from the tubing and columns. The CD34 ϩ cell separation was then performed using the computer program. The CD34 ϩ cell selection was concluded in approximately 30 min, and the CD34 ϩ cells were eluted in 40 ml PBS buffer into a collection bag attached to the tubing set. CD34 ϩ cells were obtained from the collection bag aseptically with a syringe and further analyses were performed.
Isolex 300i magnetic cell separator: Products were subjected to purification with the Isolex 300i system (Baxter Biotech, Immunotherapy Division, Irvine, CA, USA) following three washes with buffered saline. The CD34 ϩ cells are first sensitised with a murine anti-human monoclonal antibody directed against the CD34 antigen at room temperature for 30 min. The CD34 ϩ sensitised cells were then rosetted following mixing with GMP-grade paramagnetic microspheres (Dynabeads, Baxter Europe, Unterschleissheim, Germany) which are coated with a secondary polyclonal antibody that binds to the primary monoclonal CD34 ϩ antibody. The rosetted CD34 ϩ cells are then magnetically separated from the remaining non-target cells. Unrosetted cells are automatically removed from the separation chamber, while the rosetted target cells are held within the chamber by an array of magnets which are brought close to the outside of the chamber wall. Finally, the CD34 ϩ cells are released from the Dynabeads, using a peptide molecule with high affinity for the primary antibody. The peptide competes for the same antibody binding site as the CD34 antigen, and effectively drives the CD34 ϩ cells toward an unrosetted state. Once this is accomplished, the bead/antibody/peptide complex can be magnetically held within the separation chamber while the desired CD34 ϩ cells are released into a collection container.
Ceprate SC System (Cell Pro Incorporation, Bothell, WA, USA): After centrifugation at 1580 g for 5 min and wash-ing in 500 ml of PBS, cells from the buffy coat were incubated for 25 min at 22°C with 20 g/ml biotinylated anti-CD34 monoclonal antibody 12.8 with 150 ml PBS in the presence of 0.1% human serum albumen. The product was washed and resuspended in phosphate-buffered saline (PBS), 300 ml aliquots of the washed product were placed into the CEPRATE SC System and passed through a column of avidin-coated polyacrylamide beads. The CD34 ϩ absorbed and enriched product was washed, agitated and eluted with 90 ml PBS containing 10 U/ml of heparin and 4 ml of 25% HSA. The product was centrifuged at 400 g for 10 min and then resuspended for further analysis and cryopreservation.
CD34 ϩ cell enumeration
In leukapheresis products, the number of CD34 ϩ cells was enumerated before processing in accordance with recommendations previously described by the Nordic Stem Cell Laboratory Group. 25 Briefly, a sample containing 0.5-1.0 ϫ 10 6 mononuclear cells in a volume of 50 l was incubated with 50 l test or control antibody (anti-CD34 = HPCA-2-PE, control antibody = IgG1PE both from Becton Dickinson Immuno-Systems (BDIS, San Jose, CA, USA) in a final dilution 1:10. The samples were incubated 30 min at room temperature in the dark, washed two to three times and resuspended in 0.3 ml PBS containing 10% newborn calf serum. Flow cytometry analysis was performed on a FACScan (BDIS) using Cell Quest 1.1 software (BDIS) by collection of 50 000 events in list mode with debris eliminated. The estimation of CD34-positive cells was done after SSC/FL-2 marking of one positive population. In quadrant statistics the population was identified in the upper left quadrant, among cells with a side scatter profile as lymphocytic cells. The negative control was subtracted if it exceeded 0.05%.
Subsets of CD34 ϩ cells expressing lineage-specific antigens were enumerated by analysis of a minimum of 1000 cells acquired in the CD34 SSC/FL-2 gate. Cells were incubated and double stained with anti-CD34 PE or FITC-conjugated moAbs plus one of the following conjugated moAbs: anti-CD33 FITC (My 9; BDIS), or anti-CD38 PE (Leu 17 PE; BDIS), anti-GlyA FITC (DAKO, Glostrup, Denmark), or anti-CD61 FITC (BDIS), or anti-CD19 FITC (BDIS). The analytic strategy followed a simple CD34 ϩ gating based on CD34 staining and SSC (step 1) and subsequently acquisition of a minimum of 1000 CD34 ϩ double-stained cells following Quadrant Statistics and histogram analysis (step 2). The positive lineage-specific subsets were defined by help of the test antibody in question and the relevant negative control antibody by subtracting the values.
Plating efficiency evaluated by limiting dilution
A CD34-negative B lymphoid cell line (ST486C) was used for spiking experiments adding 5% tumour cells to a leukapheresis product before CD34 selection. The plating efficiency was evaluated by a technical set up including a 96-well plastic tray (Nunclon MicroWell Plates; Nunc, Roskilde, Denmark). Each experiment diluted 10-fold from 
Calculation of purity and recovery
Based on the number of CD34 ϩ cells in the product before processing and the outcome of the CD34 ϩ enrichment procedure, we have used the following formulas for the calculation:
ϩ cells ϫ total number of nucleated cells in the product. Purity of the CD34 ϩ cells = total number of CD34 ϩ events in the enriched fraction ϫ 100/total number of nucleated cells (events) in the enriched fraction.
Yield of CD34
ϩ cells = total number of CD34 ϩ cells in the enriched fraction ϫ 100/total number of CD34 ϩ cells in the starting fraction.
Recovery of CD34
ϩ cells = total number of CD34 ϩ cells in the enriched ϩ depleted fraction × 100/total number of CD34 ϩ cells in the starting fraction.
Performance of the devices was also assessed by cell viability (trypan blue exclusion) and microbiological contamination (routine blood culture) before and after cell selection.
Results

Study plan and patients
A total of 26 study patients were harvested in three different annual cohorts for CD34 ϩ cell selection by Ceprate SC (1994-1995), Amgen Cell Selection Device (1996) (1997) and Isolex300i (1997 Isolex300i ( -1998 . The patients suffering from NHL or breast cancer were present in all three cohorts.
Purity and yield of enriched CD34
ϩ cells
The median purity of the products processed by the three different devices is given in 
CD34 antigen density before and after enrichment
The mean intensity of CD34 antibody staining of cells in the starting product was higher in all separations compared to the corresponding enriched fraction following chromatography separation as shown in Figure 1a . However, this was not the case for magnetic field or bead separation (an example of magnetic field separation is given in Figure 1b) . On the contrary, we found that the mean staining intensity in the starting and enriched fraction was significantly higher compared to the CD34 ϩ cell-depleted fraction (Table 2) , supporting a selective depletion of cells with reduced CD34 class III epitope density indicating loss of late differentiated progenitors.
Selective loss indicated by CD34
ϩ subset analysis
One major question in relation to the yield is the risk for selective loss of CD34 ϩ subsets. The results from such evaluation are given in Table 3 . At the time we performed the chromatography study we did not enumerate lineagespecific subsets. Most significant, however, is the reduction Table 2 Fluorescence intensity of CD34-staining by HPCA2 PE antibody of the CD34 ϩ /CD61 ϩ subset following the selection procedure (Table 3 ). This reduction of megakaryocytic progenitors was documented in all products processed as illustrated by one representative experiment in Figure 2a and b for magnetic field and bead separation.
Magnetic field Magnetic Chromatography beads
Total recovery of CD34 ϩ cells
Calculation of the total number of CD34 ϩ cells actually recovered in the enriched as well as the depleted fraction ϩ /CD61 ϩ megakaryocytic progenitors enumerated by double staining flow cytometry with a CD34 ϩ acquisition gate, before and after separation by magnetic field (a) or bead (b) separation. The number of CD34 ϩ 61 ϩ cells among the CD34 ϩ cells analysed was 4.3% and 14%, which was reduced to 0.5% and 1.3%, respectively.
gave the results shown in Table 4 . The number of cells lost following the procedures by nonspecific adherence, catching or sticking to the tubing and bag systems was median 14%, 50% and 46% in favour of field separation.
Reduction of non-CD34 ϩ tumour cells in spiking experiments
Potential malignant cells in, for example, B cell malignancies and breast cancer passively recovered in the enriched product are part of the non-CD34 ϩ cell compartment. With the purity of 96%, 86% or 49%, the maximal potential cell compartment contaminated with tumour cells is 4%, 14% and 51%. If we first assume that the relative Table 4 Total recovery of CD34 ϩ cells following separation reduction of the tumour cell population, resulting in a contamination with 1.1, 2.9 and 13.3 ϫ 10 3 tumour cells. Spiking experiments with a CD34-negative B lymphoid cell line with a plating efficiency of 10
Magnetic field Magnetic Chromatography beads
Ϫ2
-10
Ϫ3 were performed with 5% controlled contamination in eight clinical products harvested for research use. The IMCS was subsequently used for CD34 selection and purging efficiency was evaluated by frequency analysis of clonogenic cells as described.
The plating efficiency with 5% contamination was a median of 1.8 ϫ 10 Ϫ3 (range 0.3-20 ϫ 10 Ϫ3 n = 8). Following CD34 enrichment the plating efficiency was evaluated and calculated to be median 1.1 ϫ 10 Ϫ6 (0.13-1.8 ϫ 10
Ϫ6 N = 8). The observed reduction ranged from 2-4 log with a median of 3.2 ϫ 10 Ϫ3 (1.1-12 ϫ 10
Ϫ3
) which is not different from the expected reduction calculated above (0.3-7 ϫ 10
).
Discussion
A number of methods have been established preclinically or clinically for isolation of CD34 ϩ progenitor cells. All employ one of many monoclonal antibodies, e.g 12.8, Bl.3C5, ICH3, Q-Bend 10 or 9C5 which target different epitopes on the human CD34 antigen. 1, 2, 26 The principle in most methods is collection of antibody-sensitised cells into a solid phase such as magnetic mesh or beads, plastic plates or columns of nonmagnetic particles, while nontarget cells remain in suspension.
These devices' capacity to sensitise, catch and subsequently enrich CD34 ϩ cells do not differ significantly, as they are based on highly selected class II antibodies, optimised to sensitise the target maximally. However, nonspecific adherence and the presence of a 'dead space' (void volume) may impair the purity. First, non-specific and CD34-independent passive adherence to the mesh, beads, or column of non-CD34 ϩ cells which subsequently may be released and contaminate the enriched fraction will reduce purity. Second, random cells may be fixed in 'dead spaces' within the device or be caught in putative 'blind loops' of nonfloating areas and may be released during the final steps of the mechanical procedures. Consequently, we cannot expect a purity of 100% due to an unavoidable contamination by non-targeted cells, which may include unwanted cells, eg tumour cells (see below).
The three devices used in this study work with different principles and have several different manipulation steps: First, the magnetic field separator, developed by Miltenyi 27 uses paramagnetic iron-dextran particles as the 'solid phase' for collection of CD34 ϩ cells. The anti-CD34 antibody Q-BEND 10 coupled to the particles requires selection in a strong magnetic field. This is generated in a column filled with metallic mesh, surrounded by an externally placed magnet. This magnetises the mesh and fixes the irondextran sensitised target cells with minimal binding or adherence to solid phases. Negative non-CD34 cells flow through the column and the enriched CD34 ϩ cells are then collected by demagnetisation of the mesh simply by removing the column from the magnet. The enriched cells are coated with the nanoparticles of iron-dextran, which do not appear to affect their functional properties, including engraftment. The development of a large scale clinical system has been reported by McNiece et al 27 documenting a median purity of 96% and yield 78% selected from leukapheresis products from rhG-CSF primed normal donors, starting with a 0.51% content of CD34 ϩ cells. In a subsequent clinical study in breast cancer, 28 we have confirmed these results obtaining a median purity of 95% (range 27-99%) and yield 64% (range 27-146%) from CEF/rhG-CSF primed leukapheresis products containing a median of 1.45% CD34 ϩ cells. These enriched autografts were reinfused after high-dose therapy with absolute neutrophil recovery day 9 (median, range 7-11) and platelet recovery day 11 (median, range 9-15) and no engraftment failures. Second, the magnetic 'Dynal' microbead selection is based on the advantage of a large surface area for immobilisation of the anti-CD34 monoclonal antibody within a very small volume, as described by Smeland et al. 29 The cell separator, used for the selection procedure, has been improved to allow purging of a second population of tumour cells. The Isolex 300i consists of a stand that holds a sterile disposable chamber that can be exposed to an array of permanent magnets, mounted on a sliding mechanism, and an adjustable solution pool to hold the washing buffer. The device can generate purities of 97% (median, range 87-100%) and recovery of 33% (range 17-70%) from leukapheresis products with 1.6% CD34 ϩ , harvested from patients with B cell malignancies. 15 In an active purging protocol in multiple myeloma we have been able to confirm these findings with purities of 80-99%, and recoveries from 30-80%. Such products allow recovery of neutrophils and platelets in transplanted patients as fast as historical controls (NSCL-G/NMS-G, unpublished observations). Third, the original immunoabsorption technique is based on the use of the anti-CD34 antibody 12.8, which is biotinylated and applied to a column of avidin-coated sephadex beads. 4, 11 The cells expressing the CD34 antigen are retained, and the unlabelled cells are washed through the columns. The retained cells are fixed by the strong binding of biotin-avidin and released by gentle mechanical agitation. The clinical device has been evaluated in several clinical trials with median purity of 78% and yield of 28% in breast cancer patients 30 and mean purity 75% and about 50% yield in a recent multiple myeloma study. 22 Values are decreased to 45% purity and 42% yield in breast cancer 31 and purity to 70% and yield 42% in NHL patients. 32 The studies of breast cancer 30 and multiple myeloma patients 22 have shown an increased risk for delayed platelet recovery mainly due to low recoveries of CD34 ϩ cells which may correlate to a putative selective loss of megakaryocytic progenitors.
The different principles used to recover targetted CD34 ϩ cells, however, delineate device differences which may be of major importance. The differences are due to the physi-cal principles used, as the magnetic field separation not only fixes the cells in a less bound state compared to beads and column adherence, but also releases cells without the physical manipulation or releasing agents used in column and bead release, respectively. These factors may explain the differences we have observed in context of purity, yield and recoveries of CD34 ϩ cells. Purities do not differ significantly between the magnetic systems. However, chromatography separation did interfere with purity, very likely due to an inappropriate dead space or blind nonfloating area in accordance with the design of the columns. Yield and recovery of CD34 ϩ cells are in favour of the magnetic field separation system due to the lack of physical manipulation or releasing agents, which seem to add uncontrollable factors and thereby affect the procedure.
There is a predictable risk of selective loss of lineagespecific CD34
ϩ subsets due to the use of class II antibodies as it has been shown very recently that class II epitopes are lost on late progenitors with class III epitopes still present. 3 
Quantitation of CD34
ϩ cells by a class III antibody has been standard for all analysis as this epitope is not blocked by class II antibodies. 1, 2, 26 The class III epitope positive but class II negative late progenitor has been described as a minor population of a few percentages. 3 All such cells may be lineage specific which explains the selective loss following selection for class II epitope-positive cells (Table 3) . Another explanation may be that lineage-committed cells express the lowest density of CD34 antigens and hence are inherently the most difficult to capture. In parallel, there is also a predictable risk for selective loss of high-density antigen-positive cells due to strong binding of such high level antibody sensitised cells to the solid phase of the devices. This explains the selective loss of CD34 bright cells by chromatography separation. The compact solid phase, combined with the unstable forces needed to break the binding, may be one of the major drawbacks of this device. However, it indicates that it may be very effective as a depletion device.
A review of the literature on engraftment of manipulated autografts strongly indicates a substantial risk for delayed platelet recovery. 22, 30, 31, 33 In a recent study performed by the NSCL-G and Nordic Myeloma Study Group we found this delay in multiple myeloma comparing actual manipulated products with unmanipulated stem cell grafts (to be published). There may be several explanations for delayed recovery including severe infections or regimen-related toxicity but most likely it is a consequence of an insufficient autograft due to impaired progenitor and stem cell quality. Two retrospective studies have indicated a significant correlation between CD34/CD61 ϩ megakaryocytic progenitor number and uncommitted CD34/CD38 Ϫ cells 34, 35 on platelet recovery. The selective loss of subsets as found in this study might impair the quality of the autograft and clinical outcome. However, prospective multicenter studies are needed to document such an effect. Before such studies can be initiated we need common reference protocols for CD34 enumeration, evaluating purity, yield and recovery as well as uncommitted and lineage-specific subsets or clonogenic assays. In particular, the flow cytometry technique has to be documented with no false positive events due to platelet adherence. 34 Hopefully, the future European work within EMBT/ISHAGE Europe will generate such reference protocols.
The risk of random cell contamination during the CD34 ϩ selection also includes contamination with tumour B or carcinoma cells. Although a 2-3 log reduction of CD34-negative tumour cell is obviously a consequence of the enrichment from 0.3-6% to 18-98% and a 8-100% yield, there is still a risk of contaminating malignant cells among the 2-82% non-CD34 ϩ cells. Imitating three different levels of 0.01, 0.1 and 1% malignant cell contaminations in the three devices one can calculate the tumour cell level in the selected fraction of the three devices. The number of tumour cells necessary for malignant regeneration may depend upon the cloning efficiency and it is presently unknown what level of tumour purging is necessary or what numbers could be responsible for relapse when it occurs. Assuming this is in the range of 1:10 3-6 and contamination is more than 10 4-6 tumour cells even with optimal selection there may still be a risk for all grafts with Ͼ0.01% contamination to contain potential tumour progenitors. The only products which can be expected purged free for tumour cells are the ones with very minimal contamination (Ͻ10
Ϫ5
) in the starting product, ie products which are documented tumour free with the most sensitive techniques for quantitation. Such calculations were supported by spiking experiments documenting a 3 log reduction of tumour cells following one CD34 selection. A further CD34 selection of such products reduced contamination to an undetectable level of clonogenic lymphoma cells in an analysis with a sensitivity Ͻ1:10 6 . Obviously, such procedures give problems in quality and safety assessment of autografts and further depletion steps directed against the tumour cells in question should be evaluated preclinically before entering into clinical controlled trials.
We propose that future studies should evaluate the influence of the unavoidable loss of lineage-specific progenitors and/or uncommitted progenitors on time to three lineage engraftment, in an attempt to reject or support the hypothesis that 'selective loss of cells during CD34 ϩ enrichment does impair the graft quality ready for reinfusion following high-dose therapy'. Devices for CD34 ϩ cell enrichment are now being used in clinical practice. However, in most trials the purity and recovery of at least some of the products have been insufficient. The quality of the enrichment should meet the standards given by the manufacturers of the devices. If not, a CD34 ϩ cell enriched autograft should be considered a procedural failure or an unsafe product and discarded. According to the literature, a safe CD34 ϩ cell enriched graft could be defined as a yield of Ͼ40-50% and a purity Ͼ80-90%. It is our conclusion that clinical devices exist; however, there is still room for improvement of this technology before the procedure results in a sufficient and safe product in clinical practice.
